Multiple sclerosis (MS) is widely considered an autoimmune disease, though scientists technically classify it as “immune-mediated” because one key piece of proof is still missing. In autoimmune diseases like type 1 diabetes or rheumatoid arthritis, researchers have pinpointed the exact molecule (antigen) that triggers the immune attack. In MS, that specific trigger hasn’t been definitively identified yet. Despite this gap, most experts treat MS as autoimmune in nature because the immune system clearly attacks the body’s own tissue.
Why the Classification Still Has a Caveat
The distinction matters more to researchers than to patients, but it’s worth understanding. An autoimmune disease requires a known self-antigen, the specific piece of your own body that your immune system mistakenly targets. In MS, the immune system destroys myelin, the protective insulation around nerve fibers in the brain and spinal cord. Researchers have strong candidates for the trigger molecule, particularly a protein on the surface of myelin called MOG. Anti-MOG antibodies have been detected in some MS patients, and elevated numbers of MOG-reactive immune cells appear in both the blood and spinal fluid of people with MS.
Still, no single antigen has been confirmed as the universal trigger across all patients. That’s the sole reason the National MS Society uses the phrase “immune-mediated” rather than “autoimmune.” In practice, this is a technicality. The disease behaves like an autoimmune condition, responds to treatments designed for autoimmune conditions, and shares genetic risk factors with other autoimmune diseases.
How the Immune System Attacks the Nervous System
MS is a chronic inflammatory disease of the central nervous system. The damage centers on the myelin sheath, the fatty coating that insulates nerve fibers and allows electrical signals to travel quickly between neurons. When myelin is stripped away, the underlying nerve fiber (axon) and eventually the nerve cell itself can be damaged. These areas of damage show up as lesions on brain MRI scans.
Several types of immune cells are involved. Certain white blood cells cross the blood-brain barrier, a protective wall that normally keeps immune cells out of the brain and spinal cord. Once inside, they target myelin directly. Some of these cells produce a chemical called glutamate that damages the cells responsible for making and maintaining myelin. As myelin breaks down, its fragments become visible to even more immune cells, creating a cycle of escalating damage. Meanwhile, a separate arm of the immune system produces antibodies against myelin proteins, adding a second line of attack.
This combination of cell-driven and antibody-driven destruction is what makes MS so complex, and why it takes multiple types of therapies to manage it effectively.
Genetic Risk Factors
MS has a strong genetic component tied to the immune system. The most significant genetic risk comes from a region on chromosome 6 that codes for proteins your immune cells use to identify threats. These surface proteins help immune cells distinguish “self” from “foreign.” A specific genetic variant called HLA-DR15 has been linked to MS since the early 1970s and remains the strongest known genetic risk factor.
What makes this variant particularly interesting is that it doesn’t just help immune cells present foreign invaders. The proteins it produces can themselves become a source of confusion for the immune system, potentially causing immune cells to mistake the body’s own myelin for something dangerous. This double role, both presenting antigens and generating misleading signals, helps explain why certain people’s immune systems turn against their own nervous tissue.
Having this genetic variant doesn’t guarantee you’ll develop MS. It increases susceptibility, but environmental factors play an equally important role in whether the disease actually develops.
Environmental Triggers
The strongest environmental risk factor identified so far is infection with the Epstein-Barr virus (EBV), the virus that causes mononucleosis. A landmark study of U.S. military personnel found that young adults who were initially EBV-negative had a 32-fold increase in MS risk after becoming infected with the virus. Nearly all people with MS have been infected with EBV, though the vast majority of people who catch EBV never develop MS. The leading theory is that the virus may train certain immune cells to cross-react with myelin proteins, essentially confusing the immune system into attacking the nervous system.
Vitamin D levels also appear to play a significant role. A Harvard Medical School study found that white individuals with vitamin D blood levels in the top 20 percent had a 62 percent lower risk of developing MS compared to those with levels in the bottom 20 percent. This may help explain why MS is more common in regions farther from the equator, where people get less sun exposure and tend to have lower vitamin D levels.
How MS Is Diagnosed
Diagnosis relies on a framework called the McDonald criteria, most recently updated in 2017. The core requirement is demonstrating that damage has occurred in at least two different areas of the central nervous system (dissemination in space) at two different points in time (dissemination in time). This can be shown through a combination of clinical symptoms and MRI findings. In some cases, a spinal fluid test showing specific immune markers called oligoclonal bands can help confirm the diagnosis earlier, even before a second episode of symptoms occurs.
The criteria also require that no other condition better explains the symptoms. This is important because several other conditions, including infections, vitamin deficiencies, and other autoimmune diseases, can mimic MS on MRI or in clinical presentation.
How Treatments Target the Immune System
The fact that every effective MS treatment works by modifying immune function is itself strong evidence for the autoimmune classification. There are now over a dozen categories of disease-modifying therapies, and each one targets a different part of the immune response.
Some treatments work by trapping immune cells in the lymph nodes so they can’t travel to the brain. Others block the specific molecules immune cells use to cross the blood-brain barrier. A newer class of drugs depletes the B cells that produce anti-myelin antibodies. One of the most aggressive approaches uses chemotherapy to wipe out the existing immune system entirely, then rebuilds it from stem cells, essentially giving patients a fresh immune system that no longer attacks their nervous tissue.
These therapies don’t cure MS, but they can dramatically reduce the frequency of relapses and slow the accumulation of disability. The broad range of options reflects just how many immune pathways are involved in the disease.
Who Gets MS
Roughly 2.9 million people worldwide live with MS, a number that has climbed from 2.3 million in 2013. The increase reflects both better diagnosis and a genuine rise in incidence in some regions. Women are affected roughly two to three times more often than men, a pattern shared with many autoimmune diseases and thought to be related to hormonal and genetic differences in immune regulation. Symptoms most commonly begin between ages 20 and 40, making it one of the leading causes of neurological disability in young adults.